2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5926 A summary of 131 cases of CD19 CAR T-cell therapy for relapsed/refractory BCR::ABL-positive acute lymphoblastic leukemia.

Xian Zhang, MD, Jing Long2, Junfang Yang3, Xiaoli Ma4, Jian Sun, N/A5, Na Kuang, BS6, Fei Wu7, Xu Han, N/A8, Xiangqun Li9, Siyu Wang, N/A10, Peihua (Peggy) Lu, MD11
1 Hebei Yanda Ludaopei Hospital, Langfang, China
2 Hebei Yanda Ludaopei Hospital, Langfang, China
3 Hebei Yanda Ludaopei Hospital, Langfang, China
4 Hebei Yanda Ludaopei Hospital, Langfang, China
5 Hebei Senlang Biotechnology, Shijiazhuang, China
6 Hebei Senlang Biotechnology, Shijiazhuang, China
7 IMUNOPHARM Technology Co., Ltd., Beijing, China
8 IMUNOPHARM Technology Co., Ltd., Beijing, China
9 Kecellitics Biotech Co., Ltd, Beijing, China, Kecellitics Biotech Co., Ltd, Beijing, China
10 Kecellitics Biotech Co., Ltd, Beijing, China
11 Hebei Yanda Ludaopei Hospital, Langfang, China

Introduction

Outcomes for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) have steadily improved with advances in tyrosine kinase inhibitors (TKIs), chemotherapy, and immunotherapies. Yet some patients remain refractory to TKIs and chemotherapy. For them, CD19-directed CAR T-cell therapy has shown remarkable efficacy. Key questions remain: Is allogeneic hematopoietic stem cell transplantation (allo-HSCT) still mandatory after CD19 CAR T-cell therapy? What are the long-term outcomes? We summarize data from 131 patients with relapsed/refractory BCR::ABL-positive ALL treated with CD19 CAR T-cell therapy..

 Methods

131 patients with relapsed/refractory (R/R) BCR::ABL-positive B-ALL received CD19 CAR T-cell therapy at our center between June 2017 and December 2024. They were enrolled in three clinical trials (NCT03173417 [Immunochina], NCT02546739 [Doing], and ChiCTR-ONC-17012829 [Senlang]). Median follow-up was 18.57 months (range: 1–74 months). Median CAR T-cell dose was 1 × 106 cells/kg. Consolidative allo-HSCT was permitted after day-30 assessment. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method and compared with the log-rank test.

Results

At day 30, hematologic CR was achieved in 123 patients (93.9%), among whom 119 (90.8%) were MRD-negative by flow cytometry (FCM) and 94 (71.7%) achieved BCR::ABL negativity by quantitative PCR. The 2-year overall survival (OS) rate was 83.6% (95% CI, 76.5%–91.5%), and the 2-year leukemia-free survival (LFS) rate was 68.0% (95% CI, 59.5%–77.6%).

Subgroup analyses were performed

Age. Twenty-nine patients (22.1%) were aged ≤14 years and 102 (77.9%) were aged >14 years. The 2-year OS rates were 88.9% vs. 81.8%, respectively (p = 0.51), and the 2-year LFS rates were 80.7% vs. 63.9%, respectively (p = 0.11).

Disease type. Of the 131 patients, 114 (87.0%) had Ph+ ALL and 17 (13.0%) had chronic myeloid leukemia in blast phase (CML-BP). The 2-year OS rates were 82.5% vs. 90.9% (p = 0.47), and the 2-year LFS rates were 65.6% vs. 85.6% (p = 0.23), respectively.

Prior transplantation. Eighty-two patients (62.6%) had no history of allo-HSCT prior to CAR T-cell therapy, whereas 49 (37.4%) had prior transplant history. The 2-year OS rates were 83.0% vs. 84.7% (p = 0.84), and the 2-year LFS rates were 73.7% vs. 57.6% (p = 0.06), respectively.

IKZF gene aberrations. Thirty-three patients (25.2%) harbored IKZF gene aberrations, and 98 (74.8%) did not. The 2-year OS rates were 87.4% vs. 82.2% (p = 0.54), and the 2-year LFS rates were 81.0% vs. 63.9% (p = 0.13), respectively.

Extramedullary disease(EMD). Forty-eight patients (36.6%) had EMD and 83 (63.4%) did not. The 2-year OS rates were 81.4% vs. 85.0% (p = 0.51), and the 2-year LFS rates were 64.5% vs. 70.0% (p = 0.41), respectively.

Pre-infusion bone marrow blasts. Eighty-five patients (64.9%) had bone marrow blasts ≤ 5% and 45 (34.4%) had blasts >5% before CAR T-cell infusion. The 2-year OS rates were 87.3% vs. 76.1% (p = 0.11), and the 2-year LFS rates were 70.0% vs. 63.2% (p = 0.26), respectively.

Day 30 BCR::ABL status. At day 30 post-infusion, 94 patients (73.4%) achieved BCR::ABL negativity and 34 (26.6%) had BCR::ABL > 0%. The 2-year OS rates were 81.8% vs. 92.6% (p = 0.33), and the 2-year LFS rates were 65.2% vs. 78.8% (p = 0.37), respectively.

Post-CART consolidation with allo-HSCT. Ninety-six patients (73.3%) proceeded to consolidative allo-HSCT after CAR T-cell therapy, while 35 (26.7%) did not. The 2-year OS rates were 85.7% vs. 76.0% (p = 0.21), and the 2-year LFS rates were 75.6% vs. 43.6% (p = 0.001), respectively.

 Conclusions

CD19 CAR T-cell therapy showed remarkable efficacy in R/R BCR::ABL-positive ALL. The FCM MRD-negative CR rate was very high (90.8%), but the BCR::ABL negativity rate was lower (71.7%). Subgroup analyses—by disease type (Ph+ ALL vs. CML-BP), age (≤14 vs. >14 years), prior allo-HSCT, IKZF aberrations, extramedullary disease, pre-infusion BM blast percentage (≤5% vs. >5%), and day-30 BCR::ABL status (0% vs. >0%)—revealed no significant differences in 2-year OS or LFS. However, patients who received consolidative allo-HSCT after CAR T-cell therapy had superior OS and significantly better LFS than those who did not. Thus, consolidative allo-HSCT should be considered the preferred post-CAR T strategy in R/R BCR::ABL-positive ALL.

Xian Zhang, MD: No relevant conflicts of interest to declare.